NKILA and non-small cell lung carcinoma: Moreover, NKILA-mediated NF-κB activation can be regarded as a therapeutic molecule since it inhibits EMT and suppresses the advancement of cancer; this is evident in breast cancer [23], hepatocellular carcinoma [24], osteosarcoma [25], and non-small-cell lung cancer [26].